Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum
tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), preliminary
antitumor ORIC-114 when administered to patients with advanced solid tumors harboring an EGFR
or HER2 alteration .